mercredi 16 mai 2018

Onco Actu du 16 mai 2018

1. Biologie

As D.I.Y. Gene Editing Gains Popularity, ‘Someone Is Going to Get Hurt’ [NY Times]

3.1.1 Prévention - Tabac - e-cigs

Florida man dies in e-cigarette explosion, police say [CNN]

4.3 Dép., diag. & prono. - Industriels

Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis [Illumina]

BioAffinity Seeking $5M for Cancer Diagnostic, Adds Board Member [Xconomy]

A Need for Speed: Illumina Acquires San Diego’s Edico Genome [Xconomy]

4.9 Dép., diag. & prono. - Sein

Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients [Agendia]

Agendia Breast Cancer Tests Adopted by French Hospital Group [Genome Web]

5.10 Traitements - Essais

New cancer clinical trial model promises to cut costs and development time [Pharmafile]

5.12.2 Immunothérapies - CAR-T

Gilead fortifies its pioneering cell therapy status, expanding into three new facilities and teaming with NCI [EndPoints]

5.12.4 Immunothérapies - Essais

Patient Registries to Bolster Cell- and Gene-Therapy Clinical Trial Data [The Scientist]

5.2 Pharma

Seattle’s Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials [EndPoints]

5.2.1 Pharma - Partenariats

Roche pens death notice for NewLink IDO/TDO cancer collab [FierceBiotech]

5.2.3 Pharma - économie

Novartis CEO Vas Narasimhan faces a heap of burning questions — but so far offers no public answers [EndPoints]

5.4 Traitements - Economie

After outcry, drugmakers decide not to triple the price of a cancer pill [Washington Post] ASCO (général) - Industriels

Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting [Myriad]

6.1 Observation

More men with low-risk prostate cancer are forgoing aggressive treatment [Washington Post]

6.10.1 Politiques (USA)

Azar threatens drugmakers with Trump's temper if they hike prices for no reason [FiercePharma]

As Trump railed against the ‘drug lobby,’ lawmakers funded by pharma watched from Rose Garden [STAT]

6.6 Publications

Why Was Springer Nature’s IPO Withdrawn? [The Scholarly Kitchen]